Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
38 hedge funds and large institutions have $28M invested in Merrimack Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 2 closing their positions.
185% more call options, than puts
Call options by funds: $801K | Put options by funds: $281K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
35% more capital invested
Capital invested by funds: $20.7M → $28M (+$7.24M)
6% more funds holding
Funds holding: 36 → 38 (+2)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bronte Capital Management
Bondi Junction,
Australia
|
+$1.95M |
| 2 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$712K |
| 3 |
NM
Newtyn Management
New York
|
+$356K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$113K |
| 5 |
LA
LVW Advisors
Pittsford,
New York
|
+$73.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$74.4K |
| 2 |
SC
Sepio Capital
Salt Lake City,
Utah
|
-$57.9K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$25K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$18.9K |
| 5 |
WR
Watson Rebecca
|
-$10K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $2K | +$1.83K | +499 | New |
|
27
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | -$217 | -59 | -15% |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$154 | -42 | -13% |
|
|
SSB
29
Sandy Spring Bank
Olney,
Maryland
| $1K | – | – | – |
|
|
TFGT
30
TS Financial Group (TSFG)
Lake Forest,
Illinois
| $1K | – | – | – |
|
31
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
32
BNP Paribas Financial Markets
Paris,
France
| $20 | – | – | – |
|
|
PAG
33
Private Advisor Group
Morristown,
New Jersey
| – | -$25K | -7,562 | Closed |
|
|
WR
34
Watson Rebecca
| – | -$10K | -3,068 | Closed |
|
35
JP Morgan Chase
New York
| – | -$2.48K | -674 | -99% |
|
36
Wells Fargo
San Francisco,
California
| – | +$15 | +4 | +3% |
|
|
AF
37
Advisornet Financial
Minnetonka,
Minnesota
| – | +$73 | +20 | New |
|
MACK Hedge Fund Activity: Q3 2020 in Review
38 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q3 2020, worth a combined $28M — up 35% from $20.7M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MACK positions and 2 closed out — a net gain of 2 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Bronte Capital Management, opening a new position worth an estimated $1.95M. The largest seller was Dimensional Fund Advisors, cutting an estimated $74.4K.
- 38 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q3 2020, up from 36 in Q2 2020.
- Funds reported $28M of Merrimack Pharmaceuticals, Inc. stock for Q3 2020, up 35% quarter-over-quarter.
- 4 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q3 2020 and 2 closed out, a net change of +2 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q3 2020 was Bronte Capital Management, an estimated $1.95M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q3 2020 was Dimensional Fund Advisors, an estimated $74.4K sold.
Based on aggregated 13F filings for Q3 2020.